NCE-1 Intelligence & Market Opportunity

Amvuttra

Vutrisiran

Neuromuscular agents

Subcutaneous Solution

Approval Date

13-Jun-22

NCE-1 Date

13-Jun-26

NCE Date

13-Jun-27

Commercial snapshot

Market performance & projections

Revenue ($M)

2314

CAGR (%)

0.391

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

4535

2027

6002

2028

7313

2029

8664

2030

10110

2031

11016

2032

11881

Molecule profile

Details & specifications

Molecule

Vutrisiran

Innovator

ALNYLAM PHARMACEUTICALS, INC.

Dosage Form

Subcutaneous Solution

Strength

EQ 25 mg base/0.5 mL (EQ 25 mg base/0.5 mL)

Therapeutic Category

Neuromuscular agents

Usage

To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.